Heat shock proteins and their use as anticancer vaccines

Clinical Cancer Research

Volumn 10, Issue 24, 2004, Pages 8142-8146

  Parmiani, Giorgio ^a   Testori, Alessandro ^b   Maio, Michele ^c   Castelli, Chiara ^a   Rivoltini, Licia ^a   Pilla, Lorenzo ^a   Belli, Filiberto ^a   Mazzaferro, Vincenzo ^a   Coppa, Jorgelina ^a   Patuzzo, Roberto ^a   Sertoli, Mario R ^d   Hoos, Axel ^e   Srivastava, Pramod K ^f   Santinami, Mario ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e Antigenics Inc   (United States)

^f UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN[571-579]; EPITHELIAL CELL ADHESION MOLECULE[263-271]; GAMMA INTERFERON; GLYCOPROTEIN GP 96; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN PEPTIDE COMPLEX 96; HLA ANTIGEN; MELAN A[27-35]; ONCOPHAGE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CYTOKINE RELEASE; DRUG ISOLATION; DRUG PROTEIN BINDING; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INNATE IMMUNITY; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; HEAT-SHOCK PROTEINS; HUMANS; NEOPLASMS;

EID: 19944425916     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1194     Document Type: Review

References (36)

1. Parmiani G, Castelli C, Dalerba P, et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst (Bethesda) 2002;94:805-18.
2. Novellino L, Parmiani G, Castelli C. A listing of human tumor antigens: March 2004 update. Cancer Immunol Immunother 2004; Aug 7 [epub ahead of print]
3. Marincola FM, Jaffe EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000;74:181-273.
4. Dudley ME, Roopenian DC. Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens. J Exp Med 1996;184:441-7.
5. Coulie PG, Ikeda H, Baurain JF, Chiari R. Antitumor immunity at work in a melanoma patient. Adv Cancer Res 1999;76:213-42.
6. Karanikas V, Colau D, Baurain JF, et al. High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res 2001;61:3718-24.
7. Novellino L, Renkvist N, Rini F, et al. Identification of a mutated receptor-like protein tyrosine phosphatase k as a novel, class II HLA-restricted melanoma antigen. J Immunol 2003;170:6363-70.
8. Suto R, Srivastava PK. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science (Wash. DC) 1995;269:1585-8.
9. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science (Wash. DC) 1997;278:117-20. Erratum in: Science (Wash. DC) 1999;19:283:preceding 1119.
10. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science (Wash. DC) 1997;278:117-20. Erratum in: Science (Wash. DC) 1999;19:283:preceding 1119.
11. Srivastava PK. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Ann Rev Immunol 2002;20:395-425.
12. Easton DP, Kaneko Y, Subjeck JR. The HSP110 and GRP170 stress proteins: newly recognized relatives of the HSP70s. Cell Stress Chaperones 2000;5:276-90.
13. Nieland TJ, Tan MC, Monne-van Muijen M, Koning F, Kruisbeek AM, van Bleek GM. Isolation of an immunodominant viral peptide that is endogenously bound to the stress protein GP96/GRP94. Proc Natl Acad Sci USA 1996;93:6135-9.
14. Ishii T, Udono H, Yamano T, et al. Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96. J Immunol 1999;162:1303-9.
15. Asea A, Rehli M, Kabingu E, et al. Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem 2002;277:15028-34.
16. Vabulas RM, Braedel S, Hilf N, et al. The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via toll-like receptor 2/4 pathway. J Biol Chem 2002;277:20840-53.
17. Rivoltini L, Castelli C, Carrabba M, et al. Human tumor-derived heat shock protein gp96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells. J Immunol 2003;171:3467-74.
18. Castelli C, Ciupitu AM, Rini F, et al. Human heat shock protein 70 peptide complexes specifically activate anti-melanoma T cells. Cancer Res 2001;61:222-7.
19. Noessner E, Gastpar R, Milani V, et al. Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells. J Immunol 2002;169:5424-32.
20. Belli F, Testori A, Rivoltini L, et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologie findings. J Clin Oncol 2002;20:4169-80.
21. Mazzaferro V, Coppa J, Carabba M, et al. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res 2003;9:3235-45.
22. Binder RJ, Anderson KM, Basu S, Srivastava PK. Cutting edge: heat shock protein gp96 induces maturation and migration of CD11c+ cells in vivo. J Immunol 2000;165:6029-35.
23. Singh-Jasuja H, Scherer HU, Hilf N, et al. The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor. Eur J Immunol 2000;30:2211-5.
24. Basu S, Binder RJ, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001;14:303-13.
25. Gastpar R, Gross C, Rossbacher L, Ellwart J, Riegger J, Multhoff G. The cell surface-localized heat shock protein 70 epitope TKD induces migration and cytolytic activity selectively in human NK cells. J Immunol 2004;172:972-80.
26. Wallin RPA, Lundqvist A, Morè SH, von Bonin A, Kiessling R, Ljunggren H-G. Heat-shock proteins as activators of the innate immune system. Trends Immunol 2002;23:130-5.
27. Palliser D, Huang Q, Hacohen N, et al. A role of toll-like receptor 4 in dendritic cell activation and cytolytic CD8+ T cell differentiation in response to a recombinant heat shock fusion protein. J Immunol 2004;172:2885-93.
28. MacAry PA, Javid B, Andres Floto R, et al. HSP70 peptide binding mutants separate antigen delivery from dendritic cell stimulation. Immunity 2004;20:95-106.
29. Janetzki S, Palla D, Rosenhauer V, Lochs H, Lewis JJ, Srivastava PK. Immunization of cancer patients with autologous cancer derived heat shock protein gp96 preparations: a pilot study. Int J Cancer 2000;88:232-8.
30. Hoos A, Levey DL. Vaccination with heat shock protein-peptide complexes: from basic-science to clinical applications. Expert Rev Vaccines 2003;2:369-79.
31. Parmiani G, Pilla L, Pennacchioli E, et al. Phase II study of HSPPC-96 in combination with GM-CSF and IFN-alpha in stage IV malignant melanoma. Proc Am Soc Clin Oncol Annu Meet 2004;709.
32. Bancherau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Res 2001;61:6451-8.
33. Kirkwood JM, Lee S, Land S, et al. E1696: final analysis of the clinical and immunological results of a multicenter ECOG phase II trial of multi-epitope peptide vaccination for stage IV melanoma with MART-1(27-35), gp100(209-217, 210M), and tyrosinase (368-376, 370D) (MGT) ± IFN-alpha2b and GM-CSF. Proc Am Soc Clin Oncol Annu Meet 2004;707.
34. Massa C, Guiducci C, Arioli I, Parenza M, Colombo MP, Melani C. Enhanced efficacy of tumor cell vaccines transfected with secretable hsp70. Cancer Res 2004;64:1502-8.
35. Manjili MH, Henderson R, Wang X-Y, Chen X, et al. Development of a recombinant HSP110-HER-2/neu vaccine using the chaperoning properties of HSP110. Cancer Res 2002;62:1737-42.
36. Nicchitta CV. Re-evaluating the role of heat-shock protein-peptide interactions in tumour immunity. Nat Rev Immunol 2003;3:427-32.